GFI Stock Recent News

GFI LATEST HEADLINES

GFI Stock News Image - zacks.com

In the closing of the recent trading day, Gold Fields (GFI) stood at $18.85, denoting a -1.26% change from the preceding trading day.

zacks.com 2025 Feb 19
GFI Stock News Image - zacks.com

Gold Fields (GFI) concluded the recent trading session at $19.38, signifying a -0.92% move from its prior day's close.

zacks.com 2025 Feb 11
GFI Stock News Image - zacks.com

Investors with an interest in Mining - Gold stocks have likely encountered both Gold Fields (GFI) and Franco-Nevada (FNV). But which of these two stocks offers value investors a better bang for their buck right now?

zacks.com 2025 Feb 07
GFI Stock News Image - zacks.com

Gold Fields (GFI) concluded the recent trading session at $17.61, signifying a +1.32% move from its prior day's close.

zacks.com 2025 Feb 04
GFI Stock News Image - zacks.com

Invest in gold stocks like AU, NFGC, GFI and ORLA for solid returns, with the metal continuing its bullish run amid inflation fear.

zacks.com 2025 Feb 04
GFI Stock News Image - marketbeat.com

The trend of gold has continued its strong momentum from 2024, with the precious metal soaring to record highs in early 2025. In 2024, gold delivered an impressive return, surging over 30% for the year.

marketbeat.com 2025 Feb 04
GFI Stock News Image - zacks.com

Here is how Gold Fields (GFI) and New Gold (NGD) have performed compared to their sector so far this year.

zacks.com 2025 Feb 03
GFI Stock News Image - zacks.com

BBCP, GFI, PBPB, AKO.B and ICL have been added to the Zacks Rank #1 (Strong Buy) List on February 3, 2025.

zacks.com 2025 Feb 03
GFI Stock News Image - zacks.com

Gold Fields (GFI) reachead $16.59 at the closing of the latest trading day, reflecting a +1.22% change compared to its last close.

zacks.com 2025 Jan 29
GFI Stock News Image - seekingalpha.com

The 'Undercovered' Dozen highlights 12 lesser-covered stocks, offering investment ideas and encouraging discussions on their potential and market outlook. Beyond Inc. is rated a Strong Buy by Oskar Goyvaerts due to its turnaround plan, new CEO, and cost cuts aiming for breakeven FCF by Q3 2025. BioCGT Investor discusses the potential of Editas Medicine and Intellia Therapeutics despite market pessimism, with strategic pipeline reprioritization and significant upside targets possible.

seekingalpha.com 2025 Jan 25
10 of 50